19.00
19.00 (-0.07%)
As of Dec 23, 2020
Vincerx Pharma, Inc. [LSAC]
Source:
Company Overview
Vincerx Pharma, Inc is a clinical-stage biopharmaceutical company. Our current pipeline is entirely derived from the Bayer License Agreement, pursuant to which we have been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute (i) a versatile and adaptable bioconjugation platform, now referred to as the VersAptx platform, including next-generation ADCs VIP943, in Phase 1 trials, and VIP924, in preclinical studies, and VIP236, an SMDC, on Phase 1 trials, and (ii) a small molecule drug program, including enitociclib, a P-TEFb/CDK9 inhibitor in an NIH-sponsored Phase 1 trial.
| Country | United States |
| Headquarters | palo alto, california |
| Phone Number | 650-800-6676 |
| Industry | manufacturing |
| CEO | Dr. Ahmed M. Hamdy |
| Website | vincerx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-31.5 |
| Net Income | $-30.1 |
| Net Cash | $-7.8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -229.4% |
| Profit as % of Stockholder Equity | -1,104% |
Management Effectiveness
| Return on Equity | -1,104% |
| Return on Assets | -375.7% |
| Turnover Ratio | |
| EBITA | $-31.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $8 |
| Total Liabilities | $5.3 |
| Operating Cash Flow | $-26.1 |
| Investing Cash Flow | $0.2 |
| Financing Cash Flow | $18 |
